Monday, February 6, 2012

Advanced Renal cell carcinoma - Early PhII results point to extrordinary benefit of Personalised therapy

In an open label PhII study, AGS-003, a personalized form of immunotherapy (dendritic cell based) when added to Pfizer's Sutent ( sunitiinib) prolongs overall survival beyond 30 months in 43% of the patients as compared to just 13% of patients on the comparator arm (sunitinib alone).
All the more the only safety issues associated with AGS-003 were Grade 1 injection site reactions which occurred in 50% of the patients. The median overall survival in the AGS-003 arm was 29.3 months as compared to 11.2 months in the sutent arm.

A PhIII study involving 450 patients is planned.